<DOC>
	<DOCNO>NCT00125671</DOCNO>
	<brief_summary>The purpose study evaluate whether addition warfarin ( blood-thinning medication ) antiplatelet therapy like aspirin well antiplatelet therapy alone ( i.e . usual treatment ) prevention leg surgery , heart attack , stroke death people peripheral vascular disease .</brief_summary>
	<brief_title>Warfarin Antiplatelet Vascular Evaluation</brief_title>
	<detailed_description>Atherosclerosis underlie cause peripheral vascular disease ( PVD ) low extremity , lead intermittent claudication , leg ulceration gangrene . More importantly , symptomatic PVD ominous sign widespread atherosclerosis present patient condition suffer threefold increase myocardial infarction ( MI ) , stroke , CV death . These CV event consequence rupture atherosclerotic plaque , lead platelet activation thrombin generation , thrombus formation occlusion critical blood vessel . Antiplatelet therapy clearly demonstrate reduce major CV event . It also reasonable expect process may attenuate addition anti-thrombin agent ( warfarin ) combination antiplatelet agent . WAVE large , international , multicentre , randomize clinical trial high-risk PVD patient evaluate additional benefit moderate intensity warfarin ( target INR 2.4-3.0 ) antiplatelet therapy compare antiplatelet therapy alone reduce serious cardiovascular event . There currently 80 active centre follow participant Canada , Poland , Australia , Hungary , China , Ukraine , Netherlands . Following randomization one two treatment group , participant require clinic phone follow-up visit every 3 month 2.5 3.5 year . For participant warfarin , INRs measure monthly frequently require . For participant stop warfarin therapy prematurely , every attempt make restart</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Intermittent claudication objective evidence PVD ( e.g . anklebrachial index [ ABI ] &lt; 0.90 ) Ischemic rest pain low limbs Ischemic nonhealing ulcer focal gangrene Amputation vascular cause Previous peripheral vascular revascularization ( angioplasty bypass surgery ) Blue toe syndrome Other significant peripheral arterial disease ( e.g . carotid stenosis ) Vascular disease evidence asymptomatic peripheral arterial disease [ PAD ] ( i.e . ABI &lt; 0.90 ) Temporary : Potential subject temporarily exclude need undergo : vascular diagnostic ( angiography ) interventional procedure ( arterial bypass graft surgery angioplasty ) ; limb amputation vascular insufficiency . Permanent : Subjects exclude follow : active bleeding high risk bleeding ; clear indication longterm warfarin use ( i.e . atrial fibrillation ) ; previous allergy intolerance warfarin ; stroke last 6 month ; renal failure require dialysis ; know significant abdominal aortic cerebral aneurysm ; peripheral arterial aneurysm ( iliac femoral ) without evidence lower limb ischemia ; significant liver disease ( i.e . cirrhosis ) ; cancer life expectancy &lt; 6 month ; anticipate nonadherence warfarin ; excessive alcohol use ; pregnancy plan become pregnant ; failure provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Warfarin Antiplatelet Vascular Evaluation</keyword>
	<keyword>Peripheral vascular disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>cardiovascular event</keyword>
	<keyword>Ischemia</keyword>
	<keyword>oral anticoagulant</keyword>
	<keyword>low ankle-brachial index</keyword>
	<keyword>moderate intensity warfarin</keyword>
	<keyword>International normalize ratio [ INR ]</keyword>
</DOC>